THE PIONEERING AGE
The company was founded in Parma in 1935 when Giacomo Chiesi, a Pharmaceutical Laboratory and embarked on his business adventure.
In the early 1940s, the laboratory began to expand and sell its products abroad, exporting drugs to Eritrea and Austria. However, as a result of World War II, part of the company was destroyed in 1944 during a bombardment, causing all activities to stop until the war ended.
When the laboratory resumed its activities, the first scientific collaborator was hired, and Chiesi launched its first penicillin-based ointment. At the time, Giacomo Chiesi began evaluating the purchase of land for the construction of a factory, which was inaugurated in 1955. It employed 50 people and produced a wide range of pharmaceutical products.
In 1966, Giacomo Chiesi handed over the management of the company to his two children, Alberto and Paolo. Chiesi Farmacêutica was a small company at the time, but it was already looking at international markets.
Alberto and Paolo began a continuous process of expansion and internationalization, with the opening of the first office abroad, located in Brazil, in the late seventies. The year 1979 represented a major milestone with the release of Clenil, a cortisone preparation indicated for asthma, allergic rhinitis and airway inflammation. Clenil continues to be a successful drug, especially in a market where effective treatments for such diseases are so few, paving the way for Chiesi Pharmaceuticals to consolidate itself in the line of respiratory diseases.
INTERNATIONALISATION AND THE THIRD CHIESI GENERATION
Following the success of Clenil, Chiesi's interest extended to anti-inflammatories and analgesics, and in 1989 the company launched Brexin, a fast-acting anti-inflammatory with good gastric tolerance. Brexin was soon marketed in more than 60 countries, certified for the United States market and now has an international patent. Almost ten years after the Brazilian adventure, the Group's international expansion is well-established, both in Europe and elsewhere.
Since 1987, Chiesi has opened branches in Pakistan, France, Spain, Greece, the UK, Austria and the Eastern European countries, the United States, Germany, Maghreb, Turkey, Bulgaria, China and Scandinavia. The Group's long-established products in the respiratory and cardiovascular areas continue to consolidate, and new products for neonatal diseases and musculoskeletal and vascular disorders have also been launched.
Chiesi’s third generation joined the company between the end of the second and the beginning of the third millennium, at different times and with different roles: Alessandro, Andrea, Giacomo and Maria Paola. Their entry has opened up new lines of research and development: Modulite® technology for respiratory products with ecological sprays, such as Foster®, a fixed anti-asthma combination delivered via a metered dose pressurized inhaler with new propellants and the development of NEXTHaler®, a powder inhaler considered the most innovative device in its class.
In 2008, Chiesi entered as a pioneer in the world of regenerative medicine, founding Holostem Advanced Therapies Ltd, and in 2013, with the acquisition of the biofarmacêutica dinamarquesa Danish biopharmaceutical company Zymenex, it moved into biotechnology, positioning itself today at the height of innovation in the biopharmaceutical sector.
40 YEARS IN BRAZIL
Chiesi's affiliate in Brazil completes 40 years of work dedicated to the development of state-of-the-art product research, offering healthcare professionals and patient drugs with Chiesi quality and reliability recognized worldwide.
A great success story that began on June 22nd, 1976. Chiesi Brasil believes in its active participation in the construction of our country, investing in the expansion of the plant in Santana de Parnaíba and seeking organic and non-organic growth within the product portfolio in which it operates.
All this thanks to the efforts and dedication of nearly 350 employees, who together promote an Excellent Company to Work for, experiencing a culture of values and a focus on people on a daily basis.